ARTL

Business Context and Reporting Period

Company: Artelo Biosciences, Inc. (ARTL)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2026
Business Overview: Artelo is a clinical-stage biopharmaceutical company developing therapeutics targeting lipid-signaling pathways, including the endocannabinoid system (ECS). Key programs include ART27.13 (cancer-related anorexia), ART26.12 (chemotherapy-induced peripheral neuropathy), and ART12.11 (CBD cocrystal). The company has incurred losses since inception and has not generated revenue.

Key Financial Metrics

Note: Q1 2025 data for Total Assets/Liabilities is not explicitly provided in the comparative balance sheet section of the text, though Q1 2025 Net Loss and EPS are available.

Material Changes vs. Prior Period

• Liquidity Surge: Cash and cash equivalents increased from $600,000 (Dec 31, 2025) to $10.3 million (Mar 31, 2026), driven by a $10.0 million net equity raise and $0.6 million in convertible note proceeds.
• Operating Expenses: Total operating expenses rose to $2.7 million from $2.4 million in Q1 2025. General and Administrative (G&A) expenses increased significantly to $1.9 million (from $1.0 million) due to professional fees related to financing activities. Research and Development (R&D) expenses decreased to $0.8 million (from $1.4 million) due to the timing of clinical activities.
• Net Loss Expansion: Net loss increased by $586,000 to $2.96 million, primarily due to increased G&A and non-cash charges related to derivative liabilities ($146,000 change in fair value) and interest expense ($124,000).
• Capital Structure: The company executed a 1-for-3 reverse stock split effective March 10, 2026. Outstanding shares increased from 673,008 to 876,032 during the quarter due to the equity offering and warrant exercises.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: Management states that conditions raise substantial doubt about the company's ability to continue as a going concern within one year, as it requires additional funding to sustain operations and clinical trials.
• Recent Financing:
  • Equity Offering: Closed March 30, 2026, raising ~$11.0 million gross ($10.0 million net) via common stock, pre-funded warrants, and common warrants.
  • Bridge Notes: Issued three convertible notes in March 2026 (Boot Capital, Vanquish, Labrys) totaling $665,000 face value. These were repaid in full in April 2026 (subsequent event).
  • Equity Line: Entered an agreement with Square Gate Capital for up to $25.0 million in potential future purchases.
• Unusual Items: Recognized a $456,000 "day-one loss" on derivative bifurcation related to the Labrys Fund II note, where the fair value of the embedded derivative exceeded proceeds. Additionally, a $146,000 loss was recorded for the net change in fair value of derivative liabilities.
• Outlook: The company expects to continue incurring losses as it advances clinical trials for ART27.13 (Phase 1b/2a) and ART26.12 (Phase 1 completed). No revenue is expected in the near future.

Investor Verification Checklist

• Cash Runway: Verify the burn rate against the $10.3 million cash balance to confirm the timeline for the next capital raise.
• Debt Repayment: Confirm the full repayment of the March 2026 bridge notes (Boot Capital, Vanquish, Labrys) as disclosed in subsequent events.
• Dilution Impact: Assess the dilution from the 10.2 million warrants outstanding and the 205,518 stock options, many of which are currently underwater or have high exercise prices.
• Clinical Milestones: Monitor enrollment and interim data for the ART27.13 CAReS trial (cancer anorexia) and the next steps for ART26.12 (CIPN).
• Derivative Liability Volatility: Review the sensitivity of the $582,000 derivative liability to stock price fluctuations, which can cause significant non-cash losses.